1. Health technology

  2. •

    Pharmaceuticals: major
Roche Holding Ltd

Roche Holding Ltd

60.94
USD
+1.76
(+2.97%)
335.14BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
6.73
6.82
6.91
7.25
7.63
8.13
8.77
8.33
9.02
10.04
9.23
9.56
9.72
- -
Basic EPS, GAAP
1.61
1.34
1.27
1.37
1.24
1.5
1.92
2.04
2
1.9
1.76
1.27
1.98
- -
Free Cash Flow per Basic Share
1.86
1.81
1.6
1.41
1.98
2.15
2.49
1.7
2.36
2.02
1.75
2.31
2
- -
Dividend per Share
0.92
0.97
1
1.01
1.02
1.04
1.06
1.1
1.12
1.14
1.16
1.17
1.19
- -
Book Value per Share
2.77
2.81
3.01
3.43
3.78
3.95
4.67
5.2
3.74
4.28
4.49
4.88
5.19
5.01
Tangible Book Value per Share
1.18
-0.45
-0.57
0.08
1.14
1.33
1.67
2.16
0.24
1.14
0.78
1.01
1.07
0.86
Basic Weighted Avg Shares
6,946
6,954
6,971
6,979
6,987
6,995
7,012
7,004
6,963
6,553
6,545
6,529
6,520
6,368
Sales/Revenue/Turnover
46,780
47,462
48,145
50,576
53,299
56,846
61,466
58,323
62,801
65,814
60,441
62,395
63,356
- -
Operating Margin (%)
35.01
29.69
28.71
27.82
24.4
25.98
28.55
31.79
28.91
26.55
25.47
21.5
29.16
- -
Depreciation Expense
2,381
2,623
3,640
3,941
3,887
3,586
4,292
4,558
4,443
3,844
3,464
3,423
3,386
- -
Net Income, GAAP
11,164
9,332
8,863
9,576
8,633
10,500
13,497
14,295
13,930
12,421
11,498
8,277
12,880
- -
Effective Tax Rate (%)
22.51
23.81
24.45
25.17
27.95
23.2
15.08
16.13
14.16
17.13
12.22
22.1
18.7
- -
Profit Margin (%)
23.86
19.66
18.41
18.93
16.2
18.47
21.96
24.51
22.18
18.87
19.02
13.27
20.33
- -
Working Capital
13,404
8,006
4,414
6,070
9,412
9,211
7,135
7,541
-2,789
6,577
8,622
13,013
10,728
6,590
LT Debt
16,423
19,347
17,100
16,992
15,839
16,077
13,547
11,096
17,101
22,282
26,092
32,097
28,674
25,222
Total Equity
21,241
21,558
23,300
26,402
29,007
30,366
35,867
39,773
28,345
32,015
33,263
36,161
37,880
36,716
Return on Invested Capital (%)
29.84
23.5
21.12
20.95
18.26
21.79
27.59
27.28
25.4
23.07
21.1
14.73
20.08
- -
Return on Capital (%)
29.52
23.01
20.28
21.27
18.59
22.09
26.96
26.23
22.89
19.89
18.78
12.39
18.18
- -
Return on Common Equity (%)
66.04
48
43.7
42.66
34.29
38.84
44.72
41.38
45.8
47.34
40.13
27.1
39.29
- -

Capital Structure

CHF

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
6,567
4,517
6,583
LT Borrowings
26,464
27,430
25,222
LT Finance Leases
- -
1,244
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6,523
6,517
6,527
Market Capitalization
210,738
266,313
270,738

Working Capital

CHF

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
35,702
38,729
35,437
Cash, Cash Equivalents & STI
12,026
15,476
9,734
Accounts Receivable, Net
11,918
12,391
12,915
Inventories
7,597
7,479
8,094
Total Current Liabilities
27,580
28,001
28,847
Payables & Accruals
- -
- -
- -
ST Debt
6,567
4,517
6,583
Deferred Revenue
- -
- -
- -

Growth Rates

CHF

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.85%
0.32%
4.75%
Free Cash Flow
4.55%
4.76%
-13.34%
Net Income, GAAP
6.11%
1.36%
55.61%
Sales/Revenue/Turnover
2.92%
1.82%
1.54%
Total Cash Common Dividend
1.08%
0.1%
1.06%

Quarterly Revenue

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
62,395
2025
- -
- -
- -
- -
63,356
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.27
2025
- -
- -
- -
- -
1.98
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.17
2025
- -
- -
- -
- -
1.19
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
Address
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Novo Nordisk A/S (NYSE:NVO)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business

Company News

Company News APIChatGPT

  • prnewswire.com

    Roche receives FDA 510(k) clearance for new cobas® eplex respiratory pathogen panel 3, enabling labs to customize respiratory testing for local patient needs

  • seekingalpha.com

    Roche: Valuation Leaves Limited Upside

  • seekingalpha.com

    Brown Advisory Flexible Equity Strategy: Q3 2026 Top Contributors And Detractors

  • globenewswire.com

    Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma

  • globenewswire.com

    Roche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratories

  • globenewswire.com

    Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades

  • fool.com

    Breakfast News: Science Strikes Back at Cancer

  • wsj.com

    Roche Targets Emerging Oncology Market With New Lung-Cancer Drug

  • reuters.com

    Roche says divarasib cut risk of death 44% in lung cancer trial

  • businesswire.com

    Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer

  • globenewswire.com

    Roche's divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer

  • businesswire.com

    Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)

  • businesswire.com

    Genentech Presents Interim Phase III Data Showing Sefaxersen Significantly Reduced Proteinuria in People With IgA Nephropathy (IgAN)

  • globenewswire.com

    Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)

  • seekingalpha.com

    Roche Holding AG (RHHBY) Q3 2026 Sales/Trading Call Transcript

  • zacks.com

    Roche's 9M 2026 Sales Rise on Strong Drug Demand, Pipeline Advances

  • wsj.com

    Roche Posts Higher Sales on Growth Across Pharma, Diagnostics Units

  • reuters.com

    Roche third quarter sales slightly beat expectations with growth across divisions

  • globenewswire.com

    [Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine […]

  • globenewswire.com

    [Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche setzt starke Dynamik im dritten Quartal mit Umsatzwachstum von +7% zu konstanten Wechselkursen (CER) und +8% in CHF fort; Konzernverkäufe steigen in den ersten neun Monaten 2026 um +6% (CER) […]